Obinutuzumab Plus Chemotherapy As First Line Treatment in Patients with Follicular Lymphoma: Experience from a Community Hospital

被引：1
|
作者：
de Una, Soraya Lorente [1 ]
Gutierrez, Javier [1 ]
Gonzalez, Matilde [1 ]
Kumar, Anjana [1 ]
Morales, Elena [1 ]
Herrada, Juan [1 ]
机构：
[1] Hosp Vithas Xanit Int, Hematol Dept, Benalmadena, Malaga, Spain
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-167896
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：12001 / 12001
页数：1
相关论文
共 50 条
  • [31] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Eliazar Sabater
    Armando López-Guillermo
    Antonio Rueda
    Antonio Salar
    Itziar Oyagüez
    Juan Manuel Collar
    Applied Health Economics and Health Policy, 2016, 14 : 465 - 477
  • [32] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Sabater, Eliazar
    Lopez-Guillermo, Armando
    Rueda, Antonio
    Salar, Antonio
    Oyaguez, Itziar
    Manuel Collar, Juan
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (04) : 465 - 477
  • [33] PHARMACOECONOMIC ANALYSIS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN SPANISH PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA
    Rubio-Terres, C.
    Gomez-Codina, J.
    Rios, Herranz E.
    Castro, A. J.
    Varela, C.
    Ray, J. A.
    VALUE IN HEALTH, 2008, 11 (06) : A481 - A481
  • [34] COST EFFECTIVENESS OF OBINUTUZUMAB PLUS CHEMOTHERAPY FOLLOWED BY OBINUTUZUMAB MAINTENANCE FOR PATIENT WITH PREVIOUSLY UNTREATED ADVANCED-STAGE FOLLICULAR LYMPHOMA IN FRENCH SETTING
    Mazaleyrat, B.
    Boissard, F.
    Ayad, S.
    Launonen, A.
    VALUE IN HEALTH, 2020, 23 : S438 - S438
  • [35] Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness Analysis
    Bellone, Marco
    Pradelli, Lorenzo
    Molica, Stefano
    De Francesco, Adele Emanuela
    Ghislieri, Daniela
    Guardalben, Emanuele
    Caputo, Antonietta
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 661 - 671
  • [36] Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma
    Ma, Jun
    Zhao, Donglu
    Zhen, Bihong
    Xia, Yan
    Gong, Qianyi
    Chen, Wendong
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (12)
  • [37] Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma
    Tam, Constantine S.
    Quach, Hang
    Nicol, Andrew
    Badoux, Xavier
    Rose, Hannah
    Prince, H. Miles
    Leahy, Michael F.
    Eek, Richard
    Wickham, Nicholas
    Patil, Sushrut S.
    Huang, Jane
    Prathikanti, Radha
    Cohen, Aileen
    Elstrom, Rebecca
    Reed, William
    Schneider, Jingjing
    Flinn, Ian W.
    BLOOD ADVANCES, 2020, 4 (19) : 4802 - 4811
  • [38] ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
    Zinzani, Pier Luigi
    Mayer, Jiri
    Flowers, Christopher R.
    Bijou, Fontanet
    De Oliveira, Ana C.
    Song, Yuqin
    Zhang, Qingyuan
    Merli, Michele
    Bouabdallah, Krimo
    Ganly, Peter
    Zhang, Huilai
    Johnson, Roderick
    Martin Garcia-Sancho, Alejandro
    Provencio Pulla, Mariano
    Trneny, Marek
    Yuen, Sam
    Tilly, Herve
    Kingsley, Edwin
    Tumyan, Gayane
    Assouline, Sarit E.
    Auer, Rebecca
    Ivanova, Elena
    Kim, Pil
    Huang, Sha
    Delarue, Richard
    Trotman, Judith
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (33) : 5107 - +
  • [39] COST-EFFECTIVENESS OF OBINUTUZUMAB PLUS BENDAMUSTINE AND FOLLOWED BY OBINUTUZUMAB MAINTENANCE THERAPY IN CHINESE PATIENTS WITH RELAPSE AND REFRACTORY FOLLICULAR LYMPHOMA
    Ma, J.
    Zhen, B.
    Xia, Y.
    Gong, Q.
    Li, Y.
    Chen, W.
    VALUE IN HEALTH, 2022, 25 (12) : S84 - S84
  • [40] Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular LymphomaAn Evidence Review Group Evaluation of the NICE Single Technology Appraisal
    Frederick W. Thielen
    Nasuh C. Büyükkaramikli
    Rob Riemsma
    Debra Fayter
    Nigel Armstrong
    Ching-Yun Wei
    Vanesa Huertas Carrera
    Kate Misso
    Gill Worthy
    Jos Kleijnen
    Isaac Corro Ramos
    PharmacoEconomics, 2019, 37 : 975 - 984
12345